Wealth Enhancement Advisory Services, LLC Zentalis Pharmaceuticals, Inc. Transaction History
Wealth Enhancement Advisory Services, LLC
- $61.1 Billion
- Q3 2025
A detailed history of Wealth Enhancement Advisory Services, LLC transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Wealth Enhancement Advisory Services, LLC holds 166,290 shares of ZNTL stock, worth $257,749. This represents 0.0% of its overall portfolio holdings.
Number of Shares
166,290
Previous 174,006
4.43%
Holding current value
$257,749
Previous $201,000
24.88%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding ZNTL
# of Institutions
123Shares Held
60.6MCall Options Held
0Put Options Held
22K-
Matrix Capital Management Company, LP Waltham, MA14MShares$21.6 Million8.42% of portfolio
-
Black Rock Inc. New York, NY4.82MShares$7.47 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.48MShares$5.39 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.88MShares$4.47 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA2.8MShares$4.34 Million0.01% of portfolio
About Zentalis Pharmaceuticals, Inc.
- Ticker ZNTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,983,600
- Market Cap $88.3M
- Description
- Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...